Clinical trials
NPC clinical trials
Below are recruiting npc clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07496190RecruitingPhase 2
Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Guangzhou, GuangdongAges 18–70 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT06829147Recruiting
AI to diagnose lymph node spread in nasopharyngeal cancer
This trial tests whether a computer model can accurately detect if cancer has spread to lymph nodes in patients with nasopharyngeal carcinoma. It uses MRI and PET/CT scans taken before treatment to see if the AI can replace or supplement current methods.
Guangzhou, GuangdongAges Any age - NCT07325539RecruitingPhase 2
Radiation and immunotherapy with chemo for nose and throat cancer
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–65 - NCT07311772RecruitingPhase 3
Testing houyanqing liquid for mouth sores during radiation
This trial tests a liquid medicine (houyanqing) to prevent or treat mouth sores caused by radiation therapy for nasopharyngeal cancer. You swish it in your mouth during radiation to see if it helps reduce pain and healing time.
Beijing, Beijing MunicipalityAges 18–75 - NCT07303023RecruitingPhase 3
Personalized neck radiation to prevent cancer spread
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT06982300RecruitingPhase 1/Phase 2
PET scan for advanced nasopharyngeal cancer
This trial tests a special PET scan that can detect a receptor (SSTR2) on cancer cells to see if it can help guide treatment for people with nasopharyngeal cancer (a type of head and neck cancer). It may help doctors choose the best therapy for you.
GroningenAges 18 years+ - NCT06846450RecruitingPhase 3
Comparing radiation types for nasopharyngeal cancer
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06788002RecruitingPhase 2
Low-dose radiation and chemoimmunotherapy for NPC with liver spread
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Changsha, HunanAges 18–70 - NCT06787456Recruiting
Screening for nasopharyngeal cancer in residents
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
Zhuhai, GuangdongAges 30–69 - NCT07796789RecruitingPhase 3
Preventing appetite loss during cancer treatment for nasopharyngeal carcinoma
This trial tests whether a medicine called nanocrystalline megestrol acetate can help prevent loss of appetite caused by chemotherapy and radiation therapy in people with nasopharyngeal carcinoma. If you are receiving chemoradiotherapy for this type of cancer, you may be able to participate.
Guangzhou, GuangdongAges 18–70 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT05514275RecruitingPhase 2
Radiation plus endostatin and capecitabine for nasopharyngeal cancer
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Hangzhou, ZhejiangAges 18–65 - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT03919552RecruitingPhase 3
Chemoradiation with two cisplatin or carboplatin plans for nasopharyngeal cancer
This Phase 3 trial compares two chemotherapy-and-radiation combinations (cisplatin-based vs carboplatin-based) for locally advanced nasopharyngeal cancer that has not spread to distant organs. It may help researchers find which plan works best while balancing safety and effectiveness.
Guangzhou, GuangdongAges 18–64 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06241599RecruitingPhase 2/Phase 3
AK104 with chemo for advanced nasopharyngeal cancer
This study tests if adding a new immunotherapy drug (called AK104) to standard chemotherapy can help people whose nasopharyngeal cancer has come back or spread after previous treatment. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06282497Recruiting
New radiation technique to reduce dry mouth in nasopharyngeal cancer
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
Zhongshan, GuangdongAges 18–70
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for npc?
- Yes. Clin2 currently lists 78 recruiting npc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a npc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a npc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.